AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

07-Apr-2015 - USA

AmpliPhi BioSciences Corporation announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, “Bacteriophage-containing Therapeutic Agents”. Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the earliest of which was previously granted in 2010.

The claims of the European patent cover various bacteriophage preparations for use in combination with antibiotics for the treatment of biofilm-related infections caused by the bacterium Pseudomonas aeruginosa. The patent claims protect the Company’s proprietary methods of bacteriophage-based treatment of bacterial infection characterized by biofilms where P. aeruginosa is present, covering the application of one or more bacteriophage preparations which target and kill P. aeruginosa in the biofilm, followed by antibiotic treatment once bacteriophage replication is established. Examples of specific treatment regimens covered include the treatment of human and animal infections resulting from a skin burn or skin wound, lung infections such as hospital acquired pneumonia (HAP) and cystic fibrosis (CF), urinary tract infection (UTI) or an infection associated with a medical device or implant. Such infections are difficult to treat as they are often resistant to antibiotic therapy.

AmpliPhi is currently developing AmpliPhage-001, a proprietary mixture of bacteriophage targeting P. aeruginosa infections in patients with CF. In collaboration with the Royal Brompton NHS Hospital London, AmpliPhage-001 is expected to enter clinical studies next year.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Astex ranked top biotech company for the second year running in The Sunday Times Microsoft Tech Track 100

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

Biotage AB Acquires Separtis Holding AG for 1.4M Euros (13M SEK) and Completes EU Distribution Consolidation

A*STAR Scientists Discover Key Component in the Mother's Egg Critical for Survival of Newly Formed Embryo

Development of wireless multi-parameter monitoring system for viruses and very slow growing microorganisms - Biophage Pharma signs collaborates with National Taiwan University

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

ES Cell International and ITI Life Sciences sign Licence Agreement for use of novel Stem Cell Technologies

To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases

Intercell reports positive results from its Phase II Pseudomonas aeruginosa investigational vaccine study

Two Hutchinson Center researchers receive prestigious awards from Damon Runyon Cancer Research Foundation - Drs. Brian Till and Colleen Delaney will use the awards for immunotherapy research